Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report
Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer. We report a case of radium-223 treatment in a 59-year-old patient with bone-only metastatic disease that progressed...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.896301/full |
| _version_ | 1811233102739013632 |
|---|---|
| author | Hélène Houssiau Francois P. Duhoux Didier François Emmanuel Seront |
| author_facet | Hélène Houssiau Francois P. Duhoux Didier François Emmanuel Seront |
| author_sort | Hélène Houssiau |
| collection | DOAJ |
| description | Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer. We report a case of radium-223 treatment in a 59-year-old patient with bone-only metastatic disease that progressed on multiple lines of systemic treatments. Radium-223 was very well tolerated and resulted in a regression of activity of bone metastases and in a 6-month progression-free survival. However, progression occurred in the liver, reflecting the fact that radium-223 should be combined with other systemic agents. This suggests that this therapeutic option is feasible and could be proposed in highly selected patients with bone metastatic disease outside of the prostate cancer field. Positron Emission Tomography appears also as a valuable tool for the evaluation of radium-223 efficacy. |
| first_indexed | 2024-04-12T11:15:54Z |
| format | Article |
| id | doaj.art-8147e274fad445d6ba3c951cddcbbb9f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T11:15:54Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8147e274fad445d6ba3c951cddcbbb9f2022-12-22T03:35:30ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-05-011210.3389/fonc.2022.896301896301Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case ReportHélène Houssiau0Francois P. Duhoux1Didier François2Emmanuel Seront3Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, BelgiumDepartment of Medical Oncology, Cliniques Universitaires Saint Luc, Brussels, BelgiumDepartment of Nuclear Medicine, Centre Hospitalier de Jolimont, Haine Saint Paul, BelgiumDepartment of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, BelgiumRadium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer. We report a case of radium-223 treatment in a 59-year-old patient with bone-only metastatic disease that progressed on multiple lines of systemic treatments. Radium-223 was very well tolerated and resulted in a regression of activity of bone metastases and in a 6-month progression-free survival. However, progression occurred in the liver, reflecting the fact that radium-223 should be combined with other systemic agents. This suggests that this therapeutic option is feasible and could be proposed in highly selected patients with bone metastatic disease outside of the prostate cancer field. Positron Emission Tomography appears also as a valuable tool for the evaluation of radium-223 efficacy.https://www.frontiersin.org/articles/10.3389/fonc.2022.896301/fullbreast cancerradium-223bone metastaseschemotherapypositron emitted tomography |
| spellingShingle | Hélène Houssiau Francois P. Duhoux Didier François Emmanuel Seront Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report Frontiers in Oncology breast cancer radium-223 bone metastases chemotherapy positron emitted tomography |
| title | Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report |
| title_full | Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report |
| title_fullStr | Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report |
| title_full_unstemmed | Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report |
| title_short | Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report |
| title_sort | radium 223 as an additional therapeutic strategy in highly selected patients with metastatic breast cancer a case report |
| topic | breast cancer radium-223 bone metastases chemotherapy positron emitted tomography |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.896301/full |
| work_keys_str_mv | AT helenehoussiau radium223asanadditionaltherapeuticstrategyinhighlyselectedpatientswithmetastaticbreastcanceracasereport AT francoispduhoux radium223asanadditionaltherapeuticstrategyinhighlyselectedpatientswithmetastaticbreastcanceracasereport AT didierfrancois radium223asanadditionaltherapeuticstrategyinhighlyselectedpatientswithmetastaticbreastcanceracasereport AT emmanuelseront radium223asanadditionaltherapeuticstrategyinhighlyselectedpatientswithmetastaticbreastcanceracasereport |